US Israel Gefen Capital Management

Gideon Saar personally directs all investment decisions, drawing on his experience building and exiting Gefen Biomed Investments on the Tel Aviv Stock Exchange. Saar's investment committee operates with support from an external scientific advisory panel that includes researchers from Tel Aviv Sourasky Medical Center and Technion — Israel Institute of Technology. His background as a former Israeli cabinet minister and MK adds a distinct regulatory and policy perspective to deal evaluation, though the firm does not invest in government-related ventures.

The firm targets late-stage Israeli life-science companies with clear regulatory pathways, alongside seed-stage medical device and diagnostics startups emerging from Israeli universities. Geographically, the focus is concentrated on Israel's Herzliya and Haifa innovation corridors, with selective co-investments in US-based companies that maintain active Israeli R&D operations. The firm participates exclusively through direct equity positions and structured co-investments, avoiding fund commitments.

Gefen Capital's investable capital base was generated through the sale and liquidation of Gefen Biomed Investments, a publicly traded medical technology holding company. Gideon Saar built the original platform on the Tel Aviv Stock Exchange as an aggregator of clinical-stage health-tech assets. The transition from a public investment vehicle to a private single-family office followed the monetization of those holdings.

No. The firm is structured as a pure single-family office and does not manage external capital, operate as a multi-family office, or raise third-party funds. All investment activity is funded exclusively by the Saar family's capital. There are no publicly known plans to convert the office into a regulated asset manager or to accept outside limited partners.

Gefen Capital has historically avoided pure-play software and consumer internet investments, focusing instead on regulated medical products, diagnostics, and life-science platforms requiring FDA or CE-mark approval. The firm also does not invest in defense technology or cybersecurity — sectors where many Israeli family offices concentrate — reflecting Saar's deliberate separation of his investment activity from his prior government portfolio. Energy and agri-food-tech investments are pursued only where clear crossover with health-sensing technologies exists.